Alembic Pharmaceuticals gets USFDA approval for Amantadine Hydrochloride Tablets

16 Oct 2020 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amantadine Hydrochloride Tablets, 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Symmetrel Tablets, 100 mg, of Endo Pharmaceuticals, Inc. (Endo). Amantadine Hydrochloride Tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Amantadine Hydrochloride Tablets, 100 mg have an estimated market size of $ 13 million for twelve months ending June, 2020 according to IQVIA.

Alembic has a cumulative total of 132 ANDA approvals (114 final approvals and 18 tentative approvals) from USFDA. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

770.25 7.35 (0.96%)
23-Feb-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.90
Dr. Reddys Lab 1297.65
Cipla 1331.40
Zydus Lifesciences 908.50
Lupin 2240.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×